RVRevolution Medicines RVMD · NASDAQ
$191.31 +0.55% (+$1.04)
- Market cap
- $40.8B
- Enterprise value
- $40.6B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -40.8%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.40
- Free float
- 90.1%
About the company
Revolution Medicines is a U.S.-based biotechnology company focused on developing innovative cancer therapies targeting specific proteins and signaling pathways associated with cancer development. The company specializes in identifying and modulating new therapeutic targets, particularly oncogenic proteins that are key to the growth and spread of cancer cells. Revolution Medicines concentrates on developing drugs that could offer a new approach to cancer treatment and improve outcomes for patients suffering from various types of cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
Mark A. Goldsmith
Employees
883
Headquarters
Redwood City
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What to watch: It missed profit estimates 8 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $815.4M against $641.9M.
- What to watch: It passes only 1 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number